A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides-Reference-Cited by-同舟云学术

A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides

Published:2024-06 Issue:2 Volume:24 Page:253-262
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Wu Xiaojie,Yu Jicheng,Ge Beikang,Wang Jeffrey,Han Xiaoran,Zhang Chunye,Mao Xiaomeng,Kalluru Hindu,Bramson Candace,Terra Steven G.,Liu Jing

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40268-024-00467-5.pdf

Reference17 articles.

1. Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42(13):8796–807. https://doi.org/10.1093/nar/gku531.

2. Insight Adis. Vupanorsen - Ionis Pharmaceuticals/Pfizer. Updated 18 Feb 2022. https://adisinsight.springer.com/drugs/800049006 Accessed 23 Feb 2022.

3. Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13(12):731–9. https://doi.org/10.1038/nrendo.2017.119.

4. Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222–32. https://doi.org/10.1056/NEJMoa1701329.

5. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41(40):3936–45. https://doi.org/10.1093/eurheartj/ehaa689.